Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations

Background: The BRAF V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoint...

Popoln opis

Bibliografske podrobnosti

Principais autores:	J. Ros, V. Navarro, G. Villacampa, I. Baraibar, F. Salvà, M. Rodriguez, C. Vaghi, A. Garcia, A. Alcaraz, J. Tabernero, E. Élez, R. Dienstmann
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-09-01
Serija:	ESMO Gastrointestinal Oncology
Teme:	surrogate markers BRAF mutation colorectal cancer targeted therapy BRAF inhibitor
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2949819825000949
Oznake:	Označite Brez oznak, prvi označite!